Mimetics of suppressor of cytokine signaling 3: Novel potential therapeutics in triple breast cancer

Sara La Manna, Eunmi Lee, Maria Ouzounova, Concetta Di Natale, Ettore Novellino, Antonello Merlino, Hasan Korkaya, Daniela Marasco

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Suppressor of cytokine signaling (SOCS) family of proteins plays critical role in the regulation of immune responses controlling JAK/STAT mediated inflammatory cytokines. Among the members, SOCS1 and SOCS3 contain a kinase inhibitory region (KIR) and SOCS3 binds to JAK/STAT/gp130 complex by inhibiting the downstream signaling and suppressing inflammatory cytokines. Loss or reduced levels of SOCS3 have been linked to cancer-associated inflammation and suppressive immunity leading to enhanced tumor growth and metastasis. In line with these reports, we previously demonstrated that proteolytic degradation of SOCS3 in triple negative breast cancer (TNBC) subtype drives the expression of inflammatory cytokines. Therefore, we postulated that SOCS3 mimetics might suppress the inflammatory cytokine production in TNBC subtype and inhibit tumor growth and metastasis. Here we designed and characterized five linear peptides derived from the N-terminal region of SOCS3 encompassing regions that interface with the JAK2/gp130 complex using the Circular Dichroism and Surface Plasmon Resonance spectroscopies. The KIRESS peptide resulted the sequence containing the most part of the hot-spots required for binding to JAK2 and was further investigated in vivo in mouse xenografts of MDA-MB-231-luci tumors as models of human TNBC subtype. Expectedly, this peptide showed a significant inhibition of primary tumor growth and pulmonary metastasis. Our studies suggest that SOCS3 peptidomimetics may possess a therapeutic potential in aggressive cancers, such as TNBC subtype, with activated inflammatory cytokines.

Original languageEnglish (US)
Pages (from-to)2177-2186
Number of pages10
JournalInternational Journal of Cancer
Volume143
Issue number9
DOIs
StatePublished - Nov 1 2018

Fingerprint

Triple Negative Breast Neoplasms
Breast Neoplasms
Cytokines
Neoplasms
Neoplasm Metastasis
Peptides
Therapeutics
Growth
Suppressor of Cytokine Signaling Proteins
Peptidomimetics
Surface Plasmon Resonance
Circular Dichroism
Heterografts
Immunity
Spectrum Analysis
Phosphotransferases
Inflammation
Lung

Keywords

  • cytokine signaling
  • mimetic peptides
  • triple breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

La Manna, S., Lee, E., Ouzounova, M., Di Natale, C., Novellino, E., Merlino, A., ... Marasco, D. (2018). Mimetics of suppressor of cytokine signaling 3: Novel potential therapeutics in triple breast cancer. International Journal of Cancer, 143(9), 2177-2186. https://doi.org/10.1002/ijc.31594

Mimetics of suppressor of cytokine signaling 3 : Novel potential therapeutics in triple breast cancer. / La Manna, Sara; Lee, Eunmi; Ouzounova, Maria; Di Natale, Concetta; Novellino, Ettore; Merlino, Antonello; Korkaya, Hasan; Marasco, Daniela.

In: International Journal of Cancer, Vol. 143, No. 9, 01.11.2018, p. 2177-2186.

Research output: Contribution to journalArticle

La Manna, S, Lee, E, Ouzounova, M, Di Natale, C, Novellino, E, Merlino, A, Korkaya, H & Marasco, D 2018, 'Mimetics of suppressor of cytokine signaling 3: Novel potential therapeutics in triple breast cancer', International Journal of Cancer, vol. 143, no. 9, pp. 2177-2186. https://doi.org/10.1002/ijc.31594
La Manna, Sara ; Lee, Eunmi ; Ouzounova, Maria ; Di Natale, Concetta ; Novellino, Ettore ; Merlino, Antonello ; Korkaya, Hasan ; Marasco, Daniela. / Mimetics of suppressor of cytokine signaling 3 : Novel potential therapeutics in triple breast cancer. In: International Journal of Cancer. 2018 ; Vol. 143, No. 9. pp. 2177-2186.
@article{6faccf6a059f4ea3b806c455a7902208,
title = "Mimetics of suppressor of cytokine signaling 3: Novel potential therapeutics in triple breast cancer",
abstract = "Suppressor of cytokine signaling (SOCS) family of proteins plays critical role in the regulation of immune responses controlling JAK/STAT mediated inflammatory cytokines. Among the members, SOCS1 and SOCS3 contain a kinase inhibitory region (KIR) and SOCS3 binds to JAK/STAT/gp130 complex by inhibiting the downstream signaling and suppressing inflammatory cytokines. Loss or reduced levels of SOCS3 have been linked to cancer-associated inflammation and suppressive immunity leading to enhanced tumor growth and metastasis. In line with these reports, we previously demonstrated that proteolytic degradation of SOCS3 in triple negative breast cancer (TNBC) subtype drives the expression of inflammatory cytokines. Therefore, we postulated that SOCS3 mimetics might suppress the inflammatory cytokine production in TNBC subtype and inhibit tumor growth and metastasis. Here we designed and characterized five linear peptides derived from the N-terminal region of SOCS3 encompassing regions that interface with the JAK2/gp130 complex using the Circular Dichroism and Surface Plasmon Resonance spectroscopies. The KIRESS peptide resulted the sequence containing the most part of the hot-spots required for binding to JAK2 and was further investigated in vivo in mouse xenografts of MDA-MB-231-luci tumors as models of human TNBC subtype. Expectedly, this peptide showed a significant inhibition of primary tumor growth and pulmonary metastasis. Our studies suggest that SOCS3 peptidomimetics may possess a therapeutic potential in aggressive cancers, such as TNBC subtype, with activated inflammatory cytokines.",
keywords = "cytokine signaling, mimetic peptides, triple breast cancer",
author = "{La Manna}, Sara and Eunmi Lee and Maria Ouzounova and {Di Natale}, Concetta and Ettore Novellino and Antonello Merlino and Hasan Korkaya and Daniela Marasco",
year = "2018",
month = "11",
day = "1",
doi = "10.1002/ijc.31594",
language = "English (US)",
volume = "143",
pages = "2177--2186",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - Mimetics of suppressor of cytokine signaling 3

T2 - Novel potential therapeutics in triple breast cancer

AU - La Manna, Sara

AU - Lee, Eunmi

AU - Ouzounova, Maria

AU - Di Natale, Concetta

AU - Novellino, Ettore

AU - Merlino, Antonello

AU - Korkaya, Hasan

AU - Marasco, Daniela

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Suppressor of cytokine signaling (SOCS) family of proteins plays critical role in the regulation of immune responses controlling JAK/STAT mediated inflammatory cytokines. Among the members, SOCS1 and SOCS3 contain a kinase inhibitory region (KIR) and SOCS3 binds to JAK/STAT/gp130 complex by inhibiting the downstream signaling and suppressing inflammatory cytokines. Loss or reduced levels of SOCS3 have been linked to cancer-associated inflammation and suppressive immunity leading to enhanced tumor growth and metastasis. In line with these reports, we previously demonstrated that proteolytic degradation of SOCS3 in triple negative breast cancer (TNBC) subtype drives the expression of inflammatory cytokines. Therefore, we postulated that SOCS3 mimetics might suppress the inflammatory cytokine production in TNBC subtype and inhibit tumor growth and metastasis. Here we designed and characterized five linear peptides derived from the N-terminal region of SOCS3 encompassing regions that interface with the JAK2/gp130 complex using the Circular Dichroism and Surface Plasmon Resonance spectroscopies. The KIRESS peptide resulted the sequence containing the most part of the hot-spots required for binding to JAK2 and was further investigated in vivo in mouse xenografts of MDA-MB-231-luci tumors as models of human TNBC subtype. Expectedly, this peptide showed a significant inhibition of primary tumor growth and pulmonary metastasis. Our studies suggest that SOCS3 peptidomimetics may possess a therapeutic potential in aggressive cancers, such as TNBC subtype, with activated inflammatory cytokines.

AB - Suppressor of cytokine signaling (SOCS) family of proteins plays critical role in the regulation of immune responses controlling JAK/STAT mediated inflammatory cytokines. Among the members, SOCS1 and SOCS3 contain a kinase inhibitory region (KIR) and SOCS3 binds to JAK/STAT/gp130 complex by inhibiting the downstream signaling and suppressing inflammatory cytokines. Loss or reduced levels of SOCS3 have been linked to cancer-associated inflammation and suppressive immunity leading to enhanced tumor growth and metastasis. In line with these reports, we previously demonstrated that proteolytic degradation of SOCS3 in triple negative breast cancer (TNBC) subtype drives the expression of inflammatory cytokines. Therefore, we postulated that SOCS3 mimetics might suppress the inflammatory cytokine production in TNBC subtype and inhibit tumor growth and metastasis. Here we designed and characterized five linear peptides derived from the N-terminal region of SOCS3 encompassing regions that interface with the JAK2/gp130 complex using the Circular Dichroism and Surface Plasmon Resonance spectroscopies. The KIRESS peptide resulted the sequence containing the most part of the hot-spots required for binding to JAK2 and was further investigated in vivo in mouse xenografts of MDA-MB-231-luci tumors as models of human TNBC subtype. Expectedly, this peptide showed a significant inhibition of primary tumor growth and pulmonary metastasis. Our studies suggest that SOCS3 peptidomimetics may possess a therapeutic potential in aggressive cancers, such as TNBC subtype, with activated inflammatory cytokines.

KW - cytokine signaling

KW - mimetic peptides

KW - triple breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85053231875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053231875&partnerID=8YFLogxK

U2 - 10.1002/ijc.31594

DO - 10.1002/ijc.31594

M3 - Article

C2 - 29752723

AN - SCOPUS:85053231875

VL - 143

SP - 2177

EP - 2186

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 9

ER -